Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Journal article
Karagiannis T. et al, (2022), Diabetologia
Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis.
Journal article
Avgerinos I. et al, (2021), Diabetes Obes Metab
Correction to: Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control.
Journal article
Tremblay J. et al, (2021), Diabetologia
Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control.
Journal article
Tremblay J. et al, (2021), Diabetologia
Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis.
Journal article
Avgerinos I. et al, (2021), Diabetes Obes Metab
Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis.
Journal article
Tsapas A. et al, (2021), Diabetes Obes Metab
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial.
Journal article
Yu J. et al, (2021), Cardiovasc Res
Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.
Journal article
Avgerinos I. et al, (2021), Diabetes Obes Metab, 23, 822 - 831
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.
Journal article
Tsapas A. et al, (2021), Ann Intern Med, 174
Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: A subanalysis of the VERIFY study.
Journal article
Chan JCN. et al, (2021), Diabetes Obes Metab, 23, 245 - 251
Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.
Journal article
Matthews DR. et al, (2020), Diabetes Obes Metab, 22, 2199 - 2203
Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes.
Journal article
Matthews D. et al, (2020), Diabetes Ther, 11, 2465 - 2476
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Journal article
Tsapas A. et al, (2020), Ann Intern Med, 173, 278 - 286
Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.
Journal article
Katulanda P. et al, (2020), Diabetologia, 63, 1440 - 1452
Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.
Journal article
Katulanda P. et al, (2020), Diabetologia, 1 - 13
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.
Journal article
Ohkuma T. et al, (2020), Diabetes Obes Metab, 22, 530 - 539
Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.
Journal article
Avgerinos I. et al, (2020), Diabetes Obes Metab, 22, 335 - 345
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
Journal article
Matthews DR. et al, (2019), Lancet, 394, 1519 - 1529
A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM.
Journal article
Matthews DR. et al, (2019), Diabetes Obes Metab, 21, 2240 - 2247